Top Stories

Why Biogen’s stock could fall 10% on new Alzheimer’s drug data


Biogen‘s stock could fall as much as 10% once it releases new data this week on its Alzheimer’s drug, aducanumab, Baird biotech analyst Brian Skorney told CNBC on Monday.

The stock could fall even further from its Monday per-share price of around $292 to about $230 if investors believe its drug will be rejected by the Food and Drug Administration, Skorney said on CNBC’s “Power Lunch.”

Shares of Biogen were down more than 2% in intraday trading Monday after Skorney wrote in a note to investors that he is skeptical Biogen’s Alzheimer’s drug will be approved by federal regulators.

“The bottom line is, the FDA standard of approval is substantial evidence of efficacy and the cumulative data for…


Jack Dorsey’s move to Africa raises questions for investors

Previous article

Dow ends nearly 270 points lower on weak manufacturing data, trade concerns

Next article

You may also like

Leave a Reply

Notify of

More in Top Stories